Dendreon seeks Chapter 11 bankruptcy as $620m debt looms
This article was originally published in Scrip
Dendreon said late on 9 November that it has reached an agreement with certain holders of its convertible senior notes due in 2016 to seek Chapter 11 bankruptcy so that it can reorganize, sell the company or dispose of its assets to manage $620m in debt that must be repaid in 14 months.
You may also be interested in...
Brainstorm’s president and CEO Chaim Lebovits talks to Scrip about the company’s progress with personalized stem cell therapy NurOwn in ALS and what the future holds for cell therapy options in neurology.
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.
ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment.